Overview and Highlights
August 2026 was defined by aggressive deal-making in metabolic disease, radiopharmaceuticals, rare diseases, and a historic wave of biotech IPOs that collectively raised over $1.2 billion in a single week. The M&A landscape was anchored by Curium's $8 billion agreement to take Lantheus private, creating a global radiopharmaceutical leader, alongside BioMarin's $275 million acquisition of Alesta Therapeutics for a first-in-class oral bone disease therapy and PTC Therapeutics' winning bid for Sangamo's BLA-stage Fabry disease gene therapy out of bankruptcy. Strategic licensing activity was equally robust, led by Roche's up-to-$2.3 billion deal with Hanmi Pharm for a non-incretin obesity drug designed to preserve lean body mass, LEO Pharma's $435 million acquisition of dersimelagon from Tanabe Pharma for two rare sunlight-triggered skin diseases, and Sentynl's $475 million option deal with Mereo BioPharma for a rare lung disease candidate.
The IPO market delivered its strongest week since the pandemic era, with Braveheart Bio ($382.5M), Latigo Biotherapeutics ($345.6M), Attovia Therapeutics ($289M), BlossomHill Therapeutics ($150M), and Vogenx ($81.3M) all pricing at or above expectations, alongside Ambros Therapeutics reaching the public markets via a reverse merger with Werewolf Therapeutics. Private equity continued to target healthcare assets, highlighted by KKR's $5.7 billion agreement to take medtech CDMO Integer Holdings private. The venture capital market saw continued support for clinical-stage programs, including Expedition Therapeutics' $115 million oversubscribed Series B for its COPD candidate. Overall, August sustained the momentum that has made 2026 one of the most active years on record for life sciences deal-making.
>$5B M&A Deals
Curium, a global radiopharmaceutical company backed by CapVest Partners, has agreed to acquire Lantheus Holdings for up to approximately $8 billion. Under the terms, Lantheus shareholders will receive $102.50 per share in cash at closing, plus contingent value rights providing for up to an additional $12.00 per share tied to sales milestones through 2030. The acquisition will combine Curium’s theranostics portfolio and global manufacturing platform with Lantheus’ U.S. radiodiagnostics business, including the prostate cancer PET imaging agent Pylarify and cardiac ultrasound enhancing agent Definity, creating a combined company serving oncology, neurology, and cardiology patients across more than 70 countries. The transaction is expected to close in the first half of 2027.
<$5B M&A Deals
Genentech, a member of the Roche Group, has entered into an exclusive licensing agreement with South Korea's Hanmi Pharm for HM17321, a proprietary urocortin-2 (UCN2) analog being developed for obesity and associated metabolic conditions. Roche is paying $190 million upfront, with total potential deal value of up to $2.3 billion including development, regulatory, and commercial milestones, plus tiered royalties on net sales. HM17321 is a first-in-class non-incretin candidate designed to simultaneously promote weight loss and preserve lean body mass, addressing a key limitation of current GLP-1-based therapies. Hanmi will complete the ongoing Phase 1 clinical trial, after which Genentech will assume development starting with Phase 2. The deal represents Roche's latest move in its stated ambition to become a top-three player in obesity.
BioMarin Pharmaceutical has entered into a definitive agreement to acquire Alesta Therapeutics, a Dutch private biotech, for $275 million upfront plus up to $215 million in development and regulatory milestone payments. The acquisition centers on ALE1, an orally active small molecule in Phase 1/2a development for hypophosphatasia (HPP), a rare genetic bone disease. If approved, ALE1 would become the first oral therapy for HPP, potentially challenging AstraZeneca's enzyme replacement therapy Strensiq. Alesta will spin out all non-ALE1 assets prior to closing, and the program will be integrated into BioMarin's Skeletal Conditions Business Unit. The transaction is expected to close in Q3 2026.
Sentynl Therapeutics, a subsidiary of Zydus Lifesciences, has entered into an option and license agreement with Mereo BioPharma potentially worth up to $475 million for the exclusive U.S. commercialization rights to alvelestat, a Phase 3-ready oral neutrophil elastase inhibitor for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). The deal includes an undisclosed upfront payment for the option, with $40 million in upfront and R&D payments upon exercise, plus up to $435 million in regulatory and commercial milestones and double-digit tiered royalties on U.S. net sales. Mereo retains ex-U.S. commercial rights and will lead the planned global Phase 3 study. Alvelestat previously demonstrated 83.5% to 93.3% reduction in neutrophil elastase activity in Phase 2 testing.
LEO Pharma has agreed to acquire worldwide rights to dersimelagon, an investigational once-daily oral melanocortin 1 receptor (MC1R) agonist, from Tanabe Pharma for up to $435 million in upfront and near-term milestone payments, plus potential downstream milestones and tiered royalties. Dersimelagon has completed Phase 3 development and an NDA was submitted to the FDA in June 2026 for the treatment of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), two rare genetic disorders that cause severe sunlight-induced skin pain. If approved, dersimelagon would become the first oral treatment option for either condition. The acquisition builds on LEO Pharma's strategy to strengthen its rare dermatology pipeline as the Danish company positions for a potential IPO.
PTC Therapeutics was selected as the winning bidder to acquire ST-920, a BLA-stage one-time administered AAV gene therapy for Fabry disease, from Sangamo Therapeutics in a competitive bankruptcy auction. The deal includes $111 million upfront and up to $100 million in contingent regulatory milestone payments, representing more than four times the value of Astellas' original stalking-horse bid. PTC plans to complete a rolling BLA submission to the FDA for accelerated approval of ST-920 in Q4 2026, with a potential commercial launch in 2027. Positive Phase 1/2 STAAR study data demonstrated improved renal function and durable enzyme activity for up to 4.5 years, with all participants able to discontinue chronic enzyme replacement therapy.
Top Precision Medicine IPOs (By Value)
1 | Braveheart Bio Raises $382.5M in Upsized IPO to Fund Cardiac Drug from Hengrui | Biotech
Braveheart Bio, a Phase 3 clinical-stage biotech developing an oral treatment for hypertrophic cardiomyopathy (HCM), priced its IPO at $18 per share, raising $382.5 million in an upsized offering of 21.25 million shares. The IPO exceeded the company's original pricing range of $15 to $17 and its initial share count of 18.75 million. Braveheart is developing a myosin inhibitor licensed from China's Hengrui Pharma as a competitor to Bristol Myers Squibb's Camzyos. The company, formed by former HI-Bio executives, began trading on the Nasdaq under the ticker "BRVE" on August 6, with shares soaring roughly 68% on the first day.
2 | Latigo Biotherapeutics Raises $345.6M in Oversubscribed IPO for Pain Drug Portfolio | Biotech
Latigo Biotherapeutics, a clinical-stage pain drug developer, completed an oversubscribed IPO raising approximately $345.6 million, more than 30% above initial expectations. The California-based company, a member of BioSpace's NextGen Class of 2025, is developing treatments for chronic pain conditions and began trading on the Nasdaq under the ticker "LTGO" on August 7. The listing adds to the 2026 IPO class, which has become the largest since the pandemic-era boom of 2021. Latigo had previously raised $135 million in a Series A (2024) and $150 million in a Series B (2025).
3 | Attovia Therapeutics Raises $289M in Upsized IPO for Immunology Pipeline | Biotech
Attovia Therapeutics, an immunology-focused biotech developing next-generation biologics for immune-mediated diseases, closed an upsized IPO raising $332 million and began trading on the Nasdaq under the ticker “ATTO” on August 5. The company’s lead programs include ATTO-1310, an anti-IL-31 therapeutic in clinical development for chronic pruritic diseases, as well as ATTO-2306, a bispecific targeting IL-31 and IL-13 for atopic dermatitis, and ATTO-1091, a trispecific targeting TL1A, IL-23p19, and integrin α4β7 for inflammatory bowel disease. All programs were internally discovered using Attovia’s ATTOBODY biparatopic biologics platform.
BlossomHill Therapeutics, a Phase 2 cancer biotech, rallied $150 million in an oversubscribed IPO listing on August 7, significantly exceeding its initial target of $111.7 million. The San Diego-based company priced approximately 9.4 million shares at $16 each and began trading on the Nasdaq under the ticker "BLSM." BlossomHill's lead candidate, BH-30643, is being developed as a challenger to AstraZeneca's Tagrisso in non-small cell lung cancer (NSCLC), with additional programs in leukemia. J.P. Morgan and Leerink Partners led the joint book-running team.
5 | Vogenx Prices $81.3M IPO at Top of Range for Metabolic Disease Drug | Biotech
Vogenx, a clinical-stage biopharmaceutical company developing treatments for metabolic diseases, closed its IPO on August 13 with $81.3 million raised at $13 per share, the high end of its range. The Raleigh, North Carolina-based company began trading on the Nasdaq Capital Market under the ticker "VOGX" on August 12. Proceeds will primarily fund Phase 2b testing of lead candidate mizagliflozin, an oral SGLT1 inhibitor licensed from Japan's Kissei Pharmaceutical, in post-bariatric hypoglycemia (PBH) and gastroparesis, both conditions with no FDA-approved pharmacological treatments. Vogenx represents the smallest IPO in the August wave but notably had raised only $11.5 million as a private company prior to going public.
Ambros Therapeutics, a clinical-stage biotech developing a treatment for complex regional pain syndrome type 1 (CRPS-1), has agreed to merge with Nasdaq-listed Werewolf Therapeutics in an all-stock reverse merger transaction, with a concurrent oversubscribed $150 million private placement. The combined company will operate as Ambros Therapeutics under the ticker "AMBX," with Ambros shareholders owning approximately 93% of the combined entity. Ambros' lead candidate neridronate, an IV bisphosphonate in-licensed from Italy's Abiogen, is in a pivotal Phase 3 trial (CRPS-RISE) for a rare chronic pain condition with no FDA-approved therapies. The drug has received Breakthrough Therapy, Fast Track, and Orphan Drug designations from the FDA. The deal is expected to close by Q1 2027.
Major Private Equity & Venture Capital Activity
1 | KKR to Take Medtech CDMO Integer Holdings Private for $5.7B | Medtech
Private equity firm KKR has entered into a definitive agreement to acquire Integer Holdings Corporation, a leading global medtech contract development and manufacturing organization (CDMO), for approximately $5.7 billion in an all-cash transaction. Integer stockholders will receive $127 per share, representing a premium of approximately 51.8% to the company's closing price on April 29, prior to its announcement of a strategic review. Integer manufactures critical components and finished products used in cardiovascular, neuromodulation, and cardiac rhythm management therapies for major medical device companies worldwide. The deal ranks among KKR's largest healthcare acquisitions since its $9.9 billion take-private of Envision Healthcare in 2018, and reflects continued private equity interest in healthcare services and medtech, following Blackstone and TPG's $18.3 billion Hologic take-private earlier this year.
Expedition Therapeutics, a clinical-stage biotechnology company developing oral small molecule therapies for inflammatory and respiratory diseases, closed an oversubscribed $115 million Series B financing led by General Atlantic, with participation from new investors RA Capital and Vivo Capital and existing backers including Sofinnova Investments, Novo Holdings, Forbion, Dawn Biopharma (a platform controlled by KKR), Sanofi Ventures, BVF Partners, and Venrock Healthcare Capital Partners. The financing coincided with the first patient dosed in a global Phase 2 clinical trial evaluating EXPD-101, a next-generation oral DPP1 inhibitor for chronic obstructive pulmonary disease (COPD), in-licensed from Shanghai-based Fosun Pharma. The round follows a $165 million Series A in October 2025, bringing total capital raised to nearly $300 million.
